SCHEMBL6285465

SCHEMBL6285465

CC1(c2ccccc2)C(=O)N(C(=O)c2ccc3ccccc3c2)C(=O)N1Cc1ccc(F)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.41
MAPK14 Q16539 4/20 0.39
HDAC6 Q9UBN7 1/20 0.39
MCHR1 Q99705 1/20 0.38
FNTA P49354 1/20 0.38
FNTB P49356 1/20 0.38
F2 P00734 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
HPGD P15428 1/20 0.37
TSHR P16473 1/20 0.37
BCHE P06276 1/20 0.37
ENPP3 O14638 1/20 0.36
ALPL P05186 1/20 0.36
XIAP P98170 1/20 0.36
NR1H4 Q96RI1 1/20 0.36
DRD4 P21917 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6285229 0.86 DRD4 (0.43) NPC1HDAC6FNTAFNTBSMN1; SMN2
SCHEMBL6282913 0.83 KMT2A (0.46) NPC1SMN1; SMN2HPGDTSHRBCHE
SCHEMBL6285454 0.82 CNR2 (0.45) FNTAFNTB
SCHEMBL6285250 0.81 CBX7 (0.40) NPC1SMN1; SMN2HPGDTSHRBCHE
SCHEMBL6283118 0.80 NPC1 (0.49) NPC1HDAC6HPGDTSHRBCHE
SCHEMBL6282978 0.78 DRD4 (0.43) NPC1HDAC6MCHR1HPGDTSHR
SCHEMBL6287299 0.74 BCHE (0.40) NPC1SMN1; SMN2HPGDTSHRBCHE
SCHEMBL6285489 0.73 DRD4 (0.46) NPC1HDAC6FNTAFNTBHPGD
SCHEMBL6282090 0.73 KMT2A (0.46) NPC1SMN1; SMN2HPGDTSHRBCHE
SCHEMBL6282035 0.72 BCHE (0.42) NPC1HPGDTSHRBCHEENPP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6919365-B2 Imidazolidinedione derivatives and use thereof as drugs SENJU PHARMACEUTICAL CO., LTD. (JP) 2005-07-19 US disclosed
US-20040110811-A1 Novel imidazolidinedione derivatives and use thereof as drugs SENJU PHARMACEUTICAL CO., LTD. (JP) 2004-06-10 US disclosed
EP-1384715-A1 NOVEL IMIDAZOLIDINEDIONE DERIVATIVES AND USE THEREOF AS DRUGS Senju Pharmaceutical Co., Ltd. (JP) 2004-01-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110811-A1 Novel imidazolidinedione derivatives and use thereof as drugs CMA1, TPSD1, TPSB2 NPC1 1028/4885MAPK14 996/4885HDAC6 491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.